Inactive Instrument

Audentes Therapeutics, Inc. Stock

US05070R1041

Biotechnology & Medical Research

Latest news : Audentes Therapeutics, Inc.

14/03/24	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI
08/11/22	Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
21/10/22	Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	CI
25/12/20	Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	CI
21/08/20	Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	CI
21/04/20	Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	CI
18/02/20	Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	CI
15/01/20	Audentes Therapeutics, Inc. Announces Management Changes	CI
15/01/20	Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	CI
15/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	CI
14/01/20	Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	CI

More news

Press Releases: Audentes Therapeutics, Inc.

15/01/20	AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	BU
16/12/19	AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
03/12/19	AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm	PR
03/12/19	AUDENTES THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

News in other languages: Audentes Therapeutics, Inc.

04/12/19	NASDAQ COMPOSITE : Wall Street poursuit son repli, un accord USA-Chine s'éloigne
03/12/19	DOW JONES 30 : Wall Street ouvre dans le rouge, un accord USA-Chine s'éloigne
03/12/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
03/12/19	USA-Les valeurs à suivre à Wall Street (actualisé)
03/12/19	Astellas Pharma : Pharmakonzern Astellas kauft für 3 Mrd Dollar US-Gentherapiespezialisten

More news

Managers and Directors: Audentes Therapeutics, Inc.

Manager	Title	Age	Since
Morten Sogaard PSD	President	-	-
Jason Schwartz CTO	Chief Tech/Sci/R&D Officer	-	01/06/2022
David Smethurst LAW	General Counsel	-	01/08/2021

Director	Title	Age	Since
Kush Parmar BRD	Director/Board Member	44	01/07/2013
Alan Beggs BRD	Director/Board Member	-	-

More insiders

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/15/20 A	Eric Mosbrooker	Tender	Executive/Senior Manager	114,669	0.2501%
1/15/20 A	Edward Conner	Tender	Chief Technology Officer	114,584	0.2499%
1/15/20 A	Mark Goldberg	Tender	Director	50,200	0.1095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AUDENTES THERAPEUTICS, INC.	-.--%	-0.03%	-	-	2.77B
ARGENX SE	-1.82%	+4.80%	+56.71%	+68.36%	57.28B
WUXI APPTEC CO., LTD.	-0.27%	+0.35%	+40.26%	+79.88%	54.99B
INSMED INCORPORATED	-2.05%	-2.14%	+0.75%	+413.38%	23.18B
BIONTECH SE	+1.97%	-1.16%	-21.00%	-13.25%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	+0.31%	-0.21%	+21.06%	-10.53%	20.46B
GENMAB A/S	+1.57%	+3.30%	+28.01%	-29.07%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.49%	+0.78%	+34.95%	+559.63%	15.67B
PHARMAESSENTIA CORPORATION	+5.29%	+1.70%	+185.09%	+333.94%	14.46B
EXELIXIS, INC.	+0.79%	+0.50%	+22.39%	+184.74%	13.92B
Average	+0.61%	+1.51%	+40.91%	+176.34%	26.68B
Weighted average by Cap.	+0.01%	+1.53%	+39.41%	+137.57%

Audentes Therapeutics, Inc. Stock

Stocks

US05070R1041

Biotechnology & Medical Research

Latest news : Audentes Therapeutics, Inc.

Press Releases: Audentes Therapeutics, Inc.

News in other languages: Audentes Therapeutics, Inc.

Managers and Directors: Audentes Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile